Auxilium Pharmaceuticals — Investor Presentation (May 2008)
40 slides from Auxilium Pharmaceuticals's investor presentation, May 1, 2008
Slide 1: May 2008
Exhibit 99.1 May 2008
Slide 2: Safe Harbor Statement
Safe Harbor Statement Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to ma
Slide 3: Slide 3
Slide 4: Auxilium Pharmaceuticals, Inc.
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) • Specialty biopharmaceutical company focused on Urologists, Endocrinologists, Orthopedists and certain PCPs • Founded in 1999 • Headquarters in Malvern, Pa. – Manufacturing in Horsham, Pa. – Approximately 32
Slide 5: Broad Maturing Pipeline
Broad Maturing Pipeline 5 6 Late Research Market Phase III Phase II Phase I Hypogonadism Dupuytren’s Contracture Peyronie’s Disease Frozen Shoulder Syndrome Overactive Bladder Broad Maturing Pipeline Note: Worldwide rights for all products available, except Testim where ex -U.S. rights have been lic
Slide 6: Anticipated News Flow Events
Anticipated News Flow Events 5 6 6 Q409 Q309 Q209 Q109 2010 Anticipated News Flow Events Q208: • XIAFLEX - Data in June • XIAFLEX - • Testim - First patient enrolled in TRiUS registry H109: • XIAFLEX - Early 2009: • XIAFLEX - Contracture Q408 Q308 Q208 Early 2010 • XIAFLEX – FDA Approval In Dupuytre
Slide 7: XIAFLEX: Unique, Late-Stage Opportunity with Blockbuster Potential
XIAFLEX™ (clostridial collagenase for injection) Unique, Late-Stage Opportunity with Blockbuster Potential
Slide 8: XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity
XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity • Potential to be first effective non-surgical treatment for two high unmet needs – Late-Stage Phase III data for the treatment of Dupuytren’s contracture -expect to file U.S. BLA in early 2009
Slide 9: Dupuytren's Contracture—a Debilitating Condition
Dupuytren’s Contracture—a Debilitating Condition Dupuytren’s Contracture—a Debilitating Condition • Excessive collagen deposition • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Debilitating effect on quality of life • Surgery is reserved
Slide 10: Dupuytren's Contracture—Unmet Medical Need
Dupuytren’s Contracture—Unmet Medical Need Dupuytren’s Contracture—Unmet Medical Need • Disease prevalence is estimated at 3%-6% among Caucasians, but occurs in all populations • Higher prevalence in patients of northern-European descent • Hereditary component in approximately 40% of patients • On a
Slide 11: XIAFLEX I.P. position for Dupuytren's Contracture
XIAFLEX I.P. position for Dupuytren’s Contracture XIAFLEX I.P. position for Dupuytren’s Contracture • Method of Use Patent in U.S. through 2014 • Use Patent in France, UK, Sweden through 2018 –Pending in Germany and Denmark • U.S. Orphan Drug Exclusivity granted on May 23, for 7 years post approval
Slide 12: Current Treatment Options Are Invasive or Ineffective
Current Treatment Options Are Invasive or Ineffective Current Treatment Options Are Invasive or Ineffective • Surgery • Non-surgical options – Splinting – Physical therapy – Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation
Slide 13: XIAFLEX—Potential to Revolutionize Treatment for Dupuytren's Contracture
XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture
Slide 14: Pivotal Phase III Study (DUPY-303): Results
Pivotal Phase III Study (DUPY-303): Results* 0/12 0/7 0/5 91% 86% 100% 85% 0% 0% 0% 0% 20% 40% 60% 80% 100% Pivotal Phase III Study (DUPY-303): Results* • 54/62 (87%) joints achieved 0°-5° contracture in the study and its open-label extension • Recurrence rates – 3 of 54 joints followed for 12 month
Slide 15: Most Patients Achieved Full Extension, Regardless of Joint Affected or Severity
Most Patients Achieved Full Extension, Regardless of Joint Affected or Severity Most Patients Achieved Full Extension, Regardless of Joint Affected or Severity 92% 78% 86% 61% 47% 53% 79% 60% 70% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% MP PIP Combined 10,000 units, approximately 0.58 mg. Joint T
Slide 16: Dupuytren's Clinical Plan
Dupuytren’s Clinical Plan Dupuytren’s Clinical Plan • CORD I Study: – 216 patients in at least 15 sites in the U.S. – Double blind placebo controlled, randomized in 2:1 ratio of active to placebo – Primary endpoint is reduction in contracture to within - 5 º of normal – Secondary endpoints to measur
Slide 17: Dupuytren's Commercial Opportunity
Dupuytren’s Commercial Opportunity We believe: • There is a pent-up demand for non-surgical therapy • Surgeons and patients prefer non-invasive treatment • Each patient on average has 2.2 joints which will require treatment; about half have contractures in both hands • Early data indicates on averag
Slide 18: Market Research Performed – Dupuytren's
Market Research Performed – Dupuytren’s Market Research Performed – Dupuytren’s • Multiple prevalence data sets proved to be highly variable in numbers of patients • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture • A combined 571
Slide 19: 240,000 Dupuytren's Candidates In U.S. & Europe Annually
240,000 Dupuytren’s Candidates In U.S. & Europe Annually Patients Seeking Treatment ~1,030,000 No Prior Surgery ~540,000 Had Surgery Previously ~490,000 Watchful Waiting ~270,000 Medical/ Surgical Treatment ~270,000 Medical/ Surgical Treatment ~125,000 Watchful Wait/ In Follow Up ~365,000 XIAFLEX Po
Slide 20: Peyronie's Disease—a Devastating Disorder
Peyronie’s Disease—a Devastating Disorder 1. Smith BH. Am J Clin Pathol . 1966;45:670-678. 2. Somers KD, Dawson DM. J Urol . 1997;157:311-315. Peyronie’s Disease—a Devastating Disorder • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Sympt
Slide 21: Epidemiology—Peyronie's Disease
Epidemiology—Peyronie’s Disease Epidemiology—Peyronie’s Disease • Prevalence of Peyronie’s disease is estimated at 1 in 20 adult men – Actual prevalence higher based on autopsies • Prevalence rate increases with age – The average age of disease onset is years • High association with other diseases s
Slide 22: Current Treatment—Surgical
Current Treatment—Surgical Current Treatment—Surgical • The goal of surgery is simply to make the two sides of the penis equal in size • Graft or prosthetic may be required
Slide 23: Peyronie's Disease—Unapproved Treatments Have Been Used With Little Reported Success
Peyronie’s Disease—Unapproved Treatments Have Been Used With Little Reported Success Peyronie’s Disease—Unapproved Treatments Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Ener
Slide 24: Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation
Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation Study 1030 58% 53% 35% 0% 20% 40% 60% 80% 100% Month 3 Month 6 Month 9 Study 1035 50% 100% 100% 89% 0% 20% 40% 60% 80% 100% Week 6 Month
Slide 25: XIAFLEX I.P. Position for Peyronie's Disease
XIAFLEX I.P. Position for Peyronie’s Disease XIAFLEX I.P. Position for Peyronie’s Disease • Method of Use Patent in U.S. through 2019 • Use Patent Granted in France, UK, and Ireland (expiry 2020) – Pending in Germany, Denmark, and Norway • U.S. Orphan Drug Exclusivity granted on March 12, 1996 for 7
Slide 26: Peyronie's Clinical Plan
Peyronie’s Clinical Plan Peyronie’s Clinical Plan • Final report of pre-clinical local effects/tolerability (ex- plaque) study under review at FDA • Phase IIb dose ranging study expected to begin in Q2 • A proprietary Patient Reported Outcome (PRO) questionnaire has been developed – To be validated
Slide 27: Market Research Performed – Peyronie's
Market Research Performed – Peyronie’s Market Research Performed – Peyronie’s • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and
Slide 28: 210,000 Peyronie's Candidates In U.S. and Europe Annually
210,000 Peyronie’s Candidates In U.S. and Europe Annually Patients Seeking Treatment ~475,000 Surgery Not Recommended ~365,000 Watchful Waiting ~160,000 Medical or Intralesional Therapy ~205,000 Surgery Recommended ~110,000 XIAFLEX Potential Candidates ~210,000 210,000 Peyronie’s Candidates In U.S.
Slide 29: XIAFLEX for Frozen Shoulder Syndrome
XIAFLEX for Frozen Shoulder Syndrome XIAFLEX for Frozen Shoulder Syndrome • Arthroscopic procedure or surgery Current treatment* • Early studies showed trend to efficacy and tolerability at highest dose (10,000 units) • Additional phase II studies needed to assess optimal dose, primary endpoints and
Slide 30: Testim 1% Testosterone Gel: Near-Term Growth Driver
Testim ® 1% Testosterone Gel: Near-Term Growth Driver Executing on Opportunities
Slide 31: Testim is the Fastest Growing Testosterone Replacement Therapy Gel
Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel • Proprietary, topical 1% testosterone gel – Once-a-day application – Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45
Slide 32: 447% +30%
447% +30%
Slide 33: Gels Fastest Growing TRT Segment
Gels Fastest Growing TRT Segment Gels Fastest Growing TRT Segment Source: IMS data ($ in millions) Gel Patch Oral Injectables $35 $117 $200 $287 $340 $383 $449 $459 $399 $302 $210 $77 $59 $49 $499 $118 $568 Gel Segment Growth ($) Mar 2008 L12M: +23.6% Gel Segment Growth ($) Gel Segment Growth ($) Ma
Slide 34: Testim quarterly net revenues and scripts: Established Track Record of Consistent Growth
Testim ® quarterly net revenues and scripts Established Track Record of Consistent Growth ® ($ in millions) Established Track Record of Consistent Growth Q1 2008 Net Revenues Y/Y Growth: +47.2% Q1 2008 Net Q1 2008 Net Revenues Revenues Y/Y Growth: Y/Y Growth: +47.2% Q1 2008 TRX YY Growth: +31.2% Q1
Slide 35: Testim Driving Growth in Market
Testim ® Driving Growth in Market Testim ® Share of TRx of Gel Market Testim ® Driving Growth in Market Source: IMS data Strong market share with high-prescribing urologists & PCP’s; 41.3% gel market share of decile 8-10 Urologists and 29.2% share with decile 8 – 10 PCP’s in March 2008 21.9% 0% 5% 1
Slide 36: Testim Patent Coverage
Testim Patent Coverage • U.S. Testim ® patent (covering Hsieh Enhancers) expires in June • ‘968 covering method of use claims for Testim issued January 22, 2008; expires 2025 • We believe no Paragraph III ANDA was filed prior to issuance of U.S. Patent # 7,320,968, since three months have passed sin
Slide 37: Financials / Strategic Priorities
Financials / Strategic Priorities
Slide 38: 1Q08 Financial Results and 2008 Guidance
1Q08 Financial Results and 2008 Guidance ($ Millions) Q1 ’07 Q1 ’08 Guidance Revenues $18.4 $27.1 $120-125 R&D Expense $8.7 $13.2 $52-56 SG&A Expense $17.2 $21.0 $88-92 Net Loss ($11.9) ($12.3) ($44-48) Stock – Based Comp Expense $1.2 $2.1 $9-11 Cash & cash equivalents $56.9 1Q08 Financial Results a
Slide 39: Strategic Priorities
Strategic Priorities Strategic Priorities • Continue Development of XIAFLEX with a plan to: – Release top line CORD I and CORD II results in June 2008 & be prepared to file BLA in early 2009 – Initiate Phase IIb in Peyronie’s Disease in Q2 2008 – Continue market research activities; prepare commerci
Slide 40: Slide 40
Auxilium Pharmaceuticals — Investor Presentation (May 2008) on 6ix